MONOCLONAL ANTIBODIES TO FETAL EPIDERMIS

人胎儿皮肤免疫荧光分析 层粘连蛋白，大疱性类天疱疮抗原， 单克隆抗体鉴定天疱疮抗原和锚定纤维抗原 抗体AF-1和AF-2。 产生了额外的单克隆抗体 从用人胎儿皮肤免疫的小鼠身上。 特异性单克隆抗体 与人表皮细胞角蛋白、人胎儿细胞角蛋白反应， 周膜带和基膜带。 改进的分离技术 来自真皮的人胎儿表皮允许小鼠用 早期的人类胎儿组织，以开发单克隆抗体 发育的早期抗原 在未来，目前开发的单克隆抗体的特异性表征 抗体将需要更密集的生化分析， 三维凝胶技术和免疫沉淀。 开发新 单克隆抗体将由用人胎儿免疫的小鼠产生 在12周胎龄之前获得的表皮组织。 进一步 体外和体内电流的发展（移植到裸鼠） 胎儿角质形成细胞培养系统可以允许产生的单克隆 抗体作为胎儿期分子控制和反应的探针 发展 此外，这些单克隆抗体将用于 鉴别良恶性表皮的连续性评价 肿瘤和遗传疾病。

Analysis of human fetal skin by immunofluorescent techniques identified sequential antigen development of laminin, bullous pemphigoid antigen, pemphigus antigen and anchoring fibril antigen identified by monoclonal antibodies AF-1 and AF-2. Additional monoclonal antibodies were generated from mice immunized with human fetal skin. Specific monoclonal antibodies generated reacted with cytokeratins of human epidermis, human fetal periderm and basement membrane zone. Improved techniques of separating human fetal epidermis from dermis have allowed mice to be immunized with earlier human fetal tissues in an effort to develop monoclonal antibodies to very early antigens of development. In the future, specific characterization of currently developed monoclonal antibodies will require more intense biochemical analysis with two dimensional gel techniques and immunoprecipitation. Development of new monoclonal antibodies will result from mice immunized with human fetal epidermal tissues obtained before 12 weeks gestational age. Further development of current in vitro and in vivo (transplanted to nude mice) fetal keratinocyte culture systems may allow the generated monoclonal antibodies to act as probes of molecular control and response during fetal development. In addition these monoclonal antibodies will be used to continue evaluation of differentiating benign and malignant epidermal neoplasms and genetic disorders.